Holen Sie sich die Stockscreener-App
4.99
1.42%
0.07
Handel nachbörslich:
5.05
0.06
+1.20%
Schlusskurs vom Vortag:
$4.92
Offen:
$4.955
24-Stunden-Volumen:
1.35M
Relative Volume:
0.23
Marktkapitalisierung:
$1.49B
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-9.5962
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
+22.91%
1M Leistung:
+49.85%
6M Leistung:
+41.76%
1J Leistung:
+60.97%
1-Tages-Spanne:
$4.955
$5.04
1-Wochen-Bereich:
$3.87
$5.82
52-Wochen-Spanne:
$1.8906
$5.82
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Vergleichen Sie ABCL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.99 | 1.47B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
What drives AbCellera Biologics Inc. stock priceExceptional ROI - Autocar Professional
AbCellera Biologics Inc. Stock Analysis and ForecastExplosive portfolio gains - Autocar Professional
AbCellera: Just Another Biotech Stock (NASDAQ:ABCL) - Seeking Alpha
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot - MSN
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? - MSN
What analysts say about AbCellera Biologics Inc. stockBreakthrough financial growth - jammulinksnews.com
Is AbCellera Biologics Inc. a good long term investmentExplosive capital gains - jammulinksnews.com
ABCL.O Surges 15.5% Intraday: A Deep Dive Into the Drivers Behind the Sharp Move - AInvest
ABCL Stock Surge: Opportunity or Caution? - StocksToTrade
AbCellera Biologics Stock (ABCL) Opinions on Recent Price Surge - Quiver Quantitative
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - Benzinga
AbCellera Biologics (ABCL) Surges 18.75% Intraday: What’s Fueling This Biotech Breakout? - AInvest
AbCellera Bets Big On AI Antibody Discovery And Partnerships - Finimize
Abcellera Biologics stock hits 52-week high at $4.46 - Investing.com Australia
AbCellera Biologics' Mysterious 8.7% Spike: What's Driving the Rally? - AInvest
Leerink Partners Initiates Coverage on AbCellera Biologics with "Outperform" Rating and $5.00 Price Target - AInvest
Abcellera Biologics stock hits 52-week high at 4.09 USD By Investing.com - Investing.com Nigeria
AbCellera's Strategic Pivot to Internal Pipelines Fuels Growth Potential in Antibody Therapies - AInvest
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
Leerink Partners Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
Abcellera Biologics stock hits 52-week high at 4.09 USD - Investing.com
AbCellera Biologics' 6% Surge: A Technical & Order-Flow Deep Dive - AInvest
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating - MSN
Leerink Partners assumes coverage on AbCellera stock with Outperform rating - Investing.com
AbCellera Biologics' Mysterious 5.7% Spike: A Technical Deep Dive - AInvest
AbCellera Biologics: Fueling Growth Through Strategic Partnerships and R&D Reinvention - AInvest
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology - Insider Monkey
AbCellera Biologics Soars 11.41% on Partnerships, Innovation - AInvest
Why Did AbCellera Biologics Jump 12%? Unraveling the Mysterious Spike - AInvest
AbCellera Biologics' 10.9% Surge Explained: Technical Momentum or Hidden Drivers? - AInvest
AbCellera shareholders approve board election and auditor - Investing.com Australia
AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria
AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):